NCT02185352: Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy, Radiation therapy

Key Eligibility Criteria:

Gender: Female
Age: 20 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: If the measurable brain lesion previously received stereotactic radiosurgery (SRS), the tumor must be a progressive lesion after radiosurgery
Exclusions: Patients with leptomeningeal metastasis; Patients who have received prior whole brain radiotherapy (WBRT); Patients who are eligible for & willing to receive brain surgery or stereotactic radiosurgery (SRS) as the initial treatment of brain metastases; Patients with prior therapy of bevacizumab, sorafenib, sunitinib, or other VEGF pathway-targeted therapy; Patients with history of disease progression or disease developed during prior cisplatin treatment

Comments are closed.

Up ↑